The measurement of complexed prostate-specific antigen has a better performance than total prostate-specific antigen

Clinical Chemistry and Laboratory Medicine

Volumn 42, Issue 9, 2004, Pages 1051-1057

  Herrmann, Wolfgang ^a   Stöckle, Michael ^a   Sand Hill, Marga ^a   Hübner, Ulrich ^a   Herrmann, Markus ^a   Obeid, Rima ^a   Wullich, Bernd ^a   Loch, Tillmann ^a   Geisel, Jürgen ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

Cancer of the prostate; Complexed prostate specific antigen; Complexed free prostate specific antigen ratio; Free prostate specific antigen; Prostate specific antigen; Screening

Indexed keywords

FINASTERIDE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; CANCER RISK; CANCER SCREENING; CONTROLLED STUDY; GERMANY; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; REFERENCE VALUE; RISK ASSESSMENT; SENSITIVITY ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; MULTIPROTEIN COMPLEXES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REFERENCE VALUES; RISK FACTORS; SENSITIVITY AND SPECIFICITY;

EID: 4744350926     PISSN: 14346621     EISSN: None     Source Type: Journal    
DOI: 10.1515/CCLM.2004.211     Document Type: Article

References (35)

1. Crawford D, Waxman S. The history of prostate specific antigen. In: Brawer MK, editor. Prostate specific antigen. New York: Marcel Dekker Inc, 2001:1-8.
2. Stephan C, Jung K, Diamandis EP, Rittenhouse HG, Lein M, Loening SA. Prostate-specific antigen, its molecular forms, and other kallikrein markers for detection of prostate cancer. Urology 2002;59:2-8.
3. Bostwick DG. Prostate-specific antigen. Current role in diagnostic pathology of prostate cancer. Am J Clin Pathol 1994;102:S31-7.
4. Lilja H, Christensson A, Dahlen U, Matikainen MT, Nilsson O, Pettersson K, et al. Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. Clin Chem 1991;37:1618-25.
5. Djavan B, Remzi M, Zlotta AR, Ravery V, Hammerer P, Reissgl A, et al. Complexed prostate-specific antigen, complexed prostate-specific antigen density of total and transition zone, complexed/total prostate-specific antigen ratio, free-to-total prostate-specific antigen ratio, density of total and transition zone prostate-specific antigen: results of the prospective multicenter European trial. Urology 2002;60:4-9.
6. Polascik TJ, Oesterling JE, Partin AW. Prostate specific antigen: a decade of discovery - what we have learned and where we am going. J Urol 1999;16:293-306.
7. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. CA Cancer J Clin 1999;49:8-31.
8. Woodrum D, French C, Shamel LB. Stability of free prostate-specific antigen in serum samples under a variety of sample collection and sample storage conditions. Urology 1996;48:33-9.
9. Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6630 men. J Urol 1994;151:1283-90.
10. Stenman UH, Leinonen J, Alfthan H, Rannikko S, Tuhkanen K, Alfthan O. A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991;51:222-6.
11. Wu JT, Liu GH. Advantages of replacing the total PSA assay with the assay for PSA-alpha 1-antichymotrypsin complex for the screening and management of prostate cancer. J Clin Lab Anal 1998;12:32-40.
12. Brawer MK, Meyer GE, Letran JL, Bankson DD, Morris DL, Yeung KK, et al. Measurement of complexed PSA improves specificity for early detection of prostate cancer. Urology 1998;52:372-8.
13. Jung K, Elgeti U, Lein M, Brux B, Sinha P, Rudolph B, et al. Ratio of free or complexed prostate-specific antigen (PSA) to total PSA: which ratio improves differentiation between benign prostatic hyperplasia and prostate cancer? Clin Chem 2000;46:55-62.
14. Catalona WJ, Smith DS, Ornstein DK. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/ml and benign prostate examination. Enhancement of specificity with free PSA measurements. J Am Med Assoc 1997;277:1452-55.
15. Okihara K, Fritsche HA, Ayala A, Johnston DA, Allard WJ, Babaian RJ. Can complexed prostate specific antigen and prostatic volume enhance prostate cancer detection in men with total prostate specific antigen between 2.5 and 4.0 ng/ml? J Urol 2001;165:1930-6.
16. Catalona WJ. Clinical utility of measurements of free and total prostate-specific antigen (PSA): a review. Prostate Suppl 1996;7:64-9.
17. Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991;324:1156-61.
18. Finne P, Auvinen A, Aro J, Juusela H, Maattanen L, Rannikko S, et al. Estimation of prostate cancer risk on the basis of total and free prostate-specific antigen, prostate volume and digital rectal examination. Eur Urol 2002;41:619-26.
19. Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. J Am Med Assoc 1998;279:1542-7.
20. Oremek GM, Sapoutzis N, Eden F, Jonas D. Complexed PSA in routine diagnosis. Anticancer Res 2003;23:975-7.
21. Allard WJ, Zhou Z, Yeung KK. Novel immunoassay for the measurement of complexed prostate-specific antigen in serum. Clin Chem 1998;44:1216-23.
22. Brawer MK, Cheli CD, Neaman IE, Goldblatt J, Smith C, Schwartz MK, et al. Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer. J Urol 2000;163:1476-80.
23. Punglia RS, D'Amico AV, Catalona WJ, Roehl KA, Kuntz KM. Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen. N Engl J Med 2003;349:335-42.
24. Lein M, Jung K, Elgeti U, Petras T, Stephan C, Brux B, et al. Comparison of the clinical validity of free prostate-specific antigen, alpha-1 antichymotrypsin-bound prostate-specific antigen and complexed prostate-specific antigen in prostate cancer diagnosis. Eur Urol 2001;39:57-64.
25. Woodrum DL, Brawer MK, Partin AW, Catalona WJ, Southwick PC. Interpretation of free prostate specific antigen clinical research studies for the detection of prostate cancer. J Urol 1998;159:5-12.
26. Vashi AR, Wojno KJ, Henricks W, England BA, Vessella RL, Lange PH, et al. Determination of the "reflex range" and appropriate cutpoints for percent free prostate-specific antigen in 413 men referred for prostatic evaluation using the AxSYM system. Urology 1997;49:19-27.
27. Junker R, Brandt B, Zechel C, Assmann G. Comparison of prostate-specific antigen (PSA) measured by four combinations of free PSA and tool PSA assays. Clin Chem 1997;43:1588-94.
28. Veltri RW, Miller MC, O'Dowd GJ, Partin AW. Impact of age on total and complexed prostate-specific antigen cutoffs in a contemporary referral series of men with prostate cancer. Urology 2002;60:47-52.
29. Cheli CD, Levine RL, Cambetas DR, Kolker JD, Roberts SB. Age-related reference ranges for complexed prostate-specific antigen and complexed/total prostate-specific antigen ratio: results from East Texas Medical Center Cancer Institute screening campaign. Urology 2002;60:53-9.
30. Sokoll LJ, Bruzek DJ, Dua R, Dunn W, Mohr P, Wallerson G, et al. Short-term stability of the molecular forms of prostate-specific antigen and effect on percent complexed prostate-specific antigen and percent free prostate-specific antigen. Urology 2002;60:24-30.
31. Piironen T, Pettersson K, Suonpaa M, Stenman UH, Oesterling JE, Lovgren T, et al. In vitro stability of free prostate-specific antigen (PSA) and prostate-specific antigen (PSA) complexed to alpha 1-antichymotrypsin in blood samples. Urology 1996;48:81-7.
32. Woodrum D, Ueno K, Uno H, Kawada Y, Akimoto S, Noda M, et al. Stability of free prostate-specific antigen in serum samples under a variety of sample collection and sample storage conditions. Urology 1996;48:33-9.
33. Kuriyama M, Ueno K, Uno H, Kawada Y, Akimoto S, Noda M, et al. Clinical evaluation of serum prostate-specific antigen-alpha1-antichymotrypsin complex values in diagnosis of prostate cancer: a cooperative study. Int J Urol 1998;5:48-54.
34. Horninger W, Cheli CD, Babaian RJ, Fritsche HA, Lepor H, Taneja SS, et al. Complexed prostate-specific antigen for early detection of prostate cancer in men with serum prostate-specific antigen levels of 2 to 4 nanograms per milliliter. Urology 2002;60:31-5.
35. Partin AW, Brawer MK, Bartsch G, Horninger W, Taneja SS, Lepor H, et al. Complexed prostate specific antigen improves specificity for prostate cancer detection: results of a prospective multicenter clinical trial. J Urol 2003;170:1787-91.